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Abstract Telomere attrition limits the replicative potential of
most somatic cells. In contrast, tumor cells acquire immortality
by continuous telomere maintenance which is predominantly due
to the transcriptional upregulation of the limiting component of
telomerase, hTERT (human telomerase reverse transcriptase).
Recent ¢ndings have provided mechanistic insight into how on-
cogenic activation as well as derepression, often due to the in-
activation of tumor suppressors, stimulate the hTERT promoter.
Knowledge gained from the study of hTERT transcriptional
regulation may prove instrumental in the development of cancer
therapies directed at the suppression of telomerase activity in
tumor cells.
# 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Telomeres are situated at the ends of linear chromosomes
and protect them from degradation as well as end-to-end fu-
sions [1]. In humans, telomeres are typically 10 kb long and
consist of TTAGGG repeats. Due to the end-replication prob-
lem telomeres erode by 50^200 bp during each round of cell
division in most somatic cells. Once telomeres shorten down
to a critical length, growth arrest or senescence is induced
thereby limiting the replicative potential of cells. This may
cause aging and aging-related diseases in human beings, and
accordingly greater telomere length has recently been corre-
lated to decreased mortality [2].
In contrast to most somatic cells, germ, stem and tumor
cells have the ability to maintain telomere length, a prerequi-
site for their unlimited replication potential. This is predom-
inantly due to the enzyme telomerase that consists of an RNA
subunit, a catalytic subunit (hTERT, human telomerase re-
verse transcriptase) and telomerase-associated proteins [3].
In vitro, the RNA subunit and hTERT are su⁄cient to elon-
gate telomeres and thus constitute the core of telomerase.
Whereas the RNA subunit of telomerase is expressed in
most cells, hTERT expression is repressed. Thus, hTERT is
the limiting component with regard to telomerase activity.
Although some tumor cells maintain telomere length by the
alternative lengthening of telomere pathway involving recom-
bination processes, s 85% of all tumor cells rather do so by
inducing telomerase activity through hTERT transcriptional
upregulation [4]. Other ways of regulating telomerase activity,
for instance by di¡erential splicing of the hTERT transcript or
posttranslational modi¢cation of the hTERT protein, also
exist [5] but appear to be more of a ¢ne-tuning on top of
hTERT promoter regulation.
Ectopic expression of hTERT has been shown to facilitate
immortalization of human cells [6] and to be required for the
transformation of human primary cells by the H-Ras and
SV40 large T antigen oncoproteins [7]. Thus, hTERT expres-
sion resulting in telomerase activity is critical for tumorigen-
esis. Furthermore, inhibition of telomerase activity leads to
senescence or apoptosis in tumor cells [8^10], indicating that
telomerase activity is required for the long-term viability of
tumor cells. However, at least in some human cell types,
transformation of cells and initial tumor formation may occur
in the absence of telomerase activation [11,12].
Altogether, telomerase expression due to the stimulation of
hTERT gene expression has clearly emerged as one hallmark
of cancer. The cloning of the hTERT promoter in 1999 [13^
16] facilitated the identi¢cation of possible mechanisms of
how hTERT transcription is upregulated in tumor cells lead-
ing ultimately to their immortalization. This review focuses in
particular on how hormone stimulation, dysregulated activity
of two families of transcription factors (E-box binding pro-
teins and ETS proteins) or viruses and, on the other hand,
loss of tumor suppressors can lead to hTERT upregulation.
2. Regulation of hTERT transcription by nuclear hormones
Estrogen is a positive regulator of cell growth in several
tumors, in particular those of the breast. Accordingly, anti-
estrogens like tamoxifen are often applied in the treatment of
breast cancer. One of estrogen’s tumor promoting e¡ects
could be the activation of hTERT gene expression, since it
can stimulate the endogenous hTERT gene and concomitantly
induce telomerase activity [17,18]. Two sites in the hTERT
promoter have been found that interact with the estrogen
receptor (ER). The ¢rst one at 32677 to 32665 (GGTC-
AAGCTGATC; Fig. 1) matches nearly the consensus ER
binding site, GGTCAN3TGACC. In vitro ER speci¢cally
bound to this site and its deletion reduced hTERT pro-
moter-mediated reporter gene activity [17]. The second
hTERT sequence (3873 GGGCGGGATGTGACC 3859)
mediating estrogen stimulation and binding ER in vitro and
in vivo [18,19] consists of a half-site for ER binding next to a
canonical recognition sequence for the transcription factor
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Sp1, GGGCGG; this juxtaposition of binding sites often al-
lows complexes of ER and Sp1 to collaboratively bind to
DNA [20]. Expectedly, tamoxifen countered estrogen-medi-
ated hTERT upregulation in breast tumor cells, but also con-
sistent with its estrogen-agonistic action in the endometrium,
tamoxifen activated hTERT expression in an endometrial can-
cer cell line [21]. Therefore, utilization of tamoxifen to sup-
press estrogen-induced telomerase activity will only be bene-
¢cial in certain cancers such as those of the breast.
Similar to estrogen, progesterone has been shown to acti-
vate hTERT transcription in breast cancer cells, yet it remains
unclear whether this is due to a direct activation of the
hTERT promoter by the cognate hormone receptor [22].
Also, androgen stimulates the hTERT promoter and telomer-
ase activity in LNCaP prostate cancer cells, but this is a de-
layed response to androgen and therefore most likely an in-
direct e¡ect of androgen on hTERT expression [23,24]. In
conclusion, steroid hormones may induce hTERT transcrip-
tion in several hormone-dependent tumors. However, hTERT
expression might also be repressed by some nuclear hormone
receptors including the vitamin D receptor (VDR), which
binds to a respective response element in the hTERT pro-
moter (Fig. 1), and retinoic acid receptor [25,26].
3. Signi¢cance of the E-boxes within the hTERT promoter
E-boxes (CACGTG) are binding sites for the Myc/Max/
Mad network of basic helix-loop-helix/leucine zipper tran-
scription factors. Central is Max that can both homodimerize
and form heterodimers with Myc and Mad proteins, resulting
in gene activation (Myc/Max) or repression (Mad/Max). Ac-
cordingly, Myc and Mad antagonize each other, and therefore
their expression levels appear to be inversely regulated, with
the proto-oncogene c-Myc being activated in proliferating and
many neoplastic cells whereas Mad genes are more promi-
nently expressed in di¡erentiating and resting cells [27]. Two
E-boxes within the hTERT promoter were identi¢ed (Fig. 1)
that mediate Myc/Max binding and transactivation
[14,15,28,29]. Expectedly, those two E-boxes also mediate re-
pression of hTERT transcription by Mad [30,31]. Indeed,
switching from Myc/Max to Mad/Max occupancy at the
hTERT promoter has been observed during di¡erentiation
of promyelocytic leukemic HL60 cells that is accompanied
by hTERT downregulation [32]. A reverse switch has been
noted upon transformation of WI-38 fetal lung ¢broblasts
that thereby acquire telomerase activity [33]. Thus, the antag-
onism between Myc and Mad proteins may be a crucial de-
terminant of hTERT expression and telomerase activity.
Two canonical and three degenerate binding sites for the
transcription factor Sp1 are localized within 110 bp upstream
of the hTERT transcription initiation site (Fig. 1) that all
interacted with Sp1 and whose mutation reduced hTERT
transcription [15,34]. Interestingly, c-Myc cooperated with
Sp1 to induce the hTERT promoter, and both transcription
factors may be overexpressed once cells pass the stage of
replicative senescence [34]. However, Sp1 and the related pro-
tein Sp3 may also under some circumstances recruit histone
deacetylases to and thereby inhibit the hTERT promoter [35].
The c-Myc gene is downregulated through the transforming
growth factor-L (TGF-L)/Smad pathway [36,37]. This may
account for how TGF-L stimulation can suppress hTERT
expression [38,39] and thereby exert one of its anti-tumorigen-
Fig. 1. Scheme of the human hTERT promoter. Documented binding sites for transcription factors regulating the hTERT promoter are indi-
cated.
Fig. 2. Regulation of hTERT transcription in tumor cells. hTERT
promoter binding proteins are boxed. Dashed arrows indicate hypo-
thetical regulatory pathways.
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ic actions (Fig. 2). Another potential way of reducing the
amount of c-Myc capable of binding to the hTERT promoter
would be by sequestering or masking of c-Myc. This may
explain how the tumor suppressor BRCA1, which forms com-
plexes with c-Myc, downregulates hTERT expression [40^42].
E-boxes are not only binding sites for Myc/Max/Mad, but
also for other proteins such as upstream stimulatory factor
(USF). Indeed, binding of both E-boxes by USF in vitro and
in vivo as well as activation of hTERT promoter constructs
by USF have been reported [43^45]. Interestingly, USF over-
expression was unable to stimulate the hTERT promoter in
telomerase-negative cells as opposed to telomerase-positive
ones, indicating that USF in itself is not su⁄cient to upregu-
late the hTERT gene during cell transformation. It may even
be that USF prevents binding of Myc/Max and thereby inap-
propriate stimulation of hTERT in normal somatic cells [45].
Finally, there are probably other E-box binding proteins that
interact with the hTERT promoter [44,46] and their contribu-
tion to hTERT regulation remains to be determined.
4. ETS proteins and hTERT transcription
ETS proteins are a family of transcription factors charac-
terized by a conserved DNA binding domain. The protago-
nists of this class of proteins, Ets1 and Ets2, can be activated
through phosphorylation by MAP kinases [47], which them-
selves are stimulated through the epidermal growth factor
(EGF) receptor and its homolog, the HER2/Neu proto-onco-
protein [48]. Interestingly, EGF stimulation can lead to
hTERT upregulation involving a promoter region encompass-
ing two juxtaposed ETS sites at 322 to 314 [49]. It was
speculated that Ets1 and Ets2 directly mediate the response
of the hTERT promoter to EGF stimulation, but at present
this hypothesis has not been supported by the demonstration
of binding of Ets1/Ets2 to the ETS sites at 322/314. Further-
more, other ETS sites may be involved in the regulation of the
hTERT promoter by Ets1/Ets2 [50], but again a more rigor-
ous analysis is required before their signi¢cance can be eval-
uated.
Recently, oncogenic HER2/Neu, Ras and Raf that all lead
to the activation of MAP kinases and its downstream e¡ector,
the ETS transcription factor ER81, have been implicated in
hTERT upregulation. Importantly, while neither HER2/Neu
(or Ras or Raf) nor ER81 alone could elicit hTERT tran-
scription in telomerase-negative cells, they together did so.
Furthermore, ER81 bound to two ETS sites at the end of
exon 1 and intron 1 (Fig. 1), and mutation of these sites
severely suppressed hTERT promoter activity. In addition,
blocking signaling from HER2/Neu to ER81 or a dominant-
negative ER81 molecule suppressed telomerase activity in a
HER2/Neu-positive breast cancer cell line [51]. Taken togeth-
er, these results may explain how activation of ER81 via the
HER2/NeuCRasCRafCMAP kinase pathway elicits telo-
merase activity in the plethora of cancer cells characterized
by oncogenic HER2/Neu, Ras or Raf.
5. Viral activation of hTERT expression
Viral DNA often integrates at chromosomal sites where
viral enhancers then drive the inappropriate expression of a
neighboring gene. This type of viral activation of hTERT gene
expression has recently been observed for hepatitis B virus
(HBV), which is an important risk factor for the development
of liver cancer, and human papillomavirus (HPV) that is one
major cause of cervical cancer [52^55].
In addition, viral proteins may directly contribute to
hTERT upregulation (Fig. 2). The HPV type 16 E6 protein,
which primarily exerts its oncogenic e¡ects by inhibiting p53,
can also associate with c-Myc and thereby activate hTERT
transcription [56^59]. Adenovirus E1A protein and the la-
tency-associated nuclear antigen (LANA) of Kaposi’s sarco-
ma-associated herpesvirus have also been reported to activate
hTERT transcription, which probably involves the Sp1 bind-
ing sites close to the transcription initiation site [60,61]. On
the other hand, hTERT transcription is downregulated by the
T-cell leukemia virus type 1 oncoprotein Tax and HPV E2
that presumably is mediated through the E-boxes and Sp1
binding sites, respectively [62,63]. On ¢rst sight, this latter
¢nding of hTERT transcription repression by tumor-associ-
ated viral proteins appears counterintuitive. However, telo-
mere attrition during early phases of tumorigenesis promotes
chromosomal aberrations and aneuploidy which may be re-
quired to cause the accumulation of mutations necessary to
establish a transformed phenotype [64]. Only after this pro-
cancer period, telomerase activation is required to maintain a
stable malignant cell phenotype, and accordingly Tax expres-
sion is downregulated upon progression to the leukemic stage
[65] and similarly E2 during progression to cervical cancer
[66].
6. Repression of the hTERT promoter
The hTERT promoter is GC-rich and located in a CpG
island, suggesting that it is regulated by methylation. How-
ever, no coherent correlation between hTERT promoter meth-
ylation and telomerase activity could be found, indicating that
CpG methylation is not the cause for the repression of
hTERT transcription in most somatic cells [67,68]. Yet, meth-
ylation may still be important for the downregulation of
hTERT expression in some cell lines [69,70] and, unexpect-
edly, in some instances hypermethylation may even contribute
to hTERT promoter activation [71].
On the other hand, hybrids of hTERT-positive tumor cells
with normal hTERT-negative cells displayed a shut-down of
all hTERT expression, suggesting that dominant repressors
mediate hTERT downregulation. Similarly, introduction of
several individual chromosomes from normal somatic cells
into tumor cells led to the suppression of hTERT expression
[72]. As such, several independent repressors of hTERT gene
transcription have been postulated to exist in normal somatic
cells.
In search of these repressors, several candidate molecules
have been identi¢ed. The Wilms’ tumor suppressor 1 (WT1)
bound to one site in the hTERT promoter (Fig. 1) and there-
by suppressed hTERT transcription [73]. Similarly, myeloid-
speci¢c zinc ¢nger protein 2 (MZF-2) interacted with a cluster
of four sites in the hTERT promoter (Fig. 1) and downregu-
lated hTERT activity [74]. However, due to the limited or
preferential expression of WT1 in kidney, gonads and spleen
and of MZF-2 in myeloid cells, those transcription factors are
unlikely to mediate hTERT suppression in most somatic cells.
A more general repressor of hTERT expression could be
p53 [75,76]. However, p53 has not been shown to directly bind
and repress the hTERT promoter. Rather, p53 forms com-
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plexes with Sp1 and may thereby prevent Sp1 from binding to
and activating the hTERT promoter [77]. Another transcrip-
tion factor, E2F-1, may also contribute to hTERT repression
as E2F-1 bound to the hTERT promoter at two sites (Fig. 1)
and reduced hTERT promoter activity in human squamous
carcinoma cells [78]. Similarly, its relatives E2F-2 and E2F-3
repressed hTERT transcription in tumor cells, whereas E2F-4
and E2F-5 did not. Stunningly, in non-transformed hTERT-
negative cells hTERT activation was observed with all of the
tested E2F-1 to -5 proteins [79] which may re£ect the paradox
that E2F can both promote and inhibit cell proliferation and
transformation. Furthermore, recruitment of the retinoblasto-
ma tumor suppressor (Rb) by E2F-1 to the hTERT promoter
might account for the fact that Rb downregulates telomerase
activity [80,81]. Two further proteins implicated in the repres-
sion of hTERT are SIP1, a DNA binding and TGF-L-regu-
lated transcription factor, and Menin, a tumor suppressor
which binds in vivo to the hTERT promoter, most likely
via to-be-identi¢ed DNA binding transcription factors [82].
7. Conclusions
Telomere attrition contributes to genomic instability and
may thereby promote the development of malignant cell trans-
formation. However, continuous telomere erosion would be
fatal even for tumor cells, which is why at later stages of
tumorigenesis telomeres are maintained in the vast majority
of cancer cells by telomerase [64]. Furthermore, telomerase
may exert functions beyond telomere lengthening during tu-
morigenesis [83,84], but at present it is unclear how it does so.
Telomerase activity is dependent on hTERT upregulation
that can be elicited in many di¡erent ways, of which probably
more than one is utilized in a tumor type-speci¢c manner.
However, two common principles have emerged for hTERT
upregulation: (i) the activation of the hTERT promoter
through oncoproteins or viral integration, and (ii) the dere-
pression of the hTERT promoter through the loss of tumor
suppressors (Fig. 2). A caveat is that the participation of
many transcription factors in hTERT regulation has been in-
ferred from studies utilizing in vitro cell cultures and should
be corroborated by studying the involvement of these tran-
scription factors in the regulation of the endogenous hTERT
gene in human tumors.
Knowledge gained from the study of hTERT transcription-
al regulation may help us to design therapies directed at the
suppression of hTERT transcription and concomitantly telo-
merase activity in cancer cells. Examples are the inhibition of
the EGF receptor or HER2/Neu leading to the suppression of
hTERT transcription [51,85], probably by abrogating the ac-
tivation of the transcription factor ER81; the inhibition of
hTERT promoter activity through VDR upon treatment
with 1K,25-dihydroxyvitamin D3 and 9-cis-retinoic acid [25] ;
and the cell type-speci¢c repression of hTERT expression by
the ER antagonist, tamoxifen [21]. Finally, the tumor-speci¢c
upregulation of the hTERT promoter destines it for targeted
cancer gene therapy. Cytotoxic or pro-apoptotic genes under
the control of the hTERT promoter will only be activated in
tumor cells and thereby protect normal cells from the indis-
criminate delivery of these genes via viral vectors [86].
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